Skip to main content
Premium Trial:

Request an Annual Quote

Dx Focus: Roche's Cobas AmpliPrep/Cobas TaqMan HCV Test v2.0

Premium

Roche said this week that it has received approval from the US Food and Drug Administration for its Cobas AmpliPrep/Cobas TaqMan HCV Test, v2.0.

Roche's assay is designed to help manage patients with chronic hepatitis C virus infection, in conjunction with clinical and laboratory markers of infection. The test quantifies hepatitis C virus RNA genotypes 1 to 6 in human EDTA plasma or serum, and can be used to predict the probability of sustained virologic response early during a course of antiviral therapy and to assess viral response to antiviral treatment, as measured by changes of HCV RNA levels.

The real-time PCR-based assay is designed for use on Roche's fully automated Cobas AmpliPrep/Cobas TaqMan System, a platform for viral load monitoring of multiple infectious diseases. The system can be combined with the Cobas p 630 instrument, which provides an integrated pre-analytical primary tube handling solution.

The Scan

Steps for Quick Review

The US Food and Drug Administration is preparing for the quick review of drugs and vaccines for the Omicron variant, according to the Wall Street Journal.

Moving Away From Using Term 'Race'

A new analysis finds that geneticists are using the term "race" in their papers less than in years past, as Science reports.

Point of the Program

The Guardian writes that some scientists have called the design of a UK newborn sequencing program into question.

Science Papers Present Multi-Omic Analysis of Lung Cells, Regulation of Cardiomyocyte Proliferation

In Science this week: a multi-omic analysis of lung cells focuses on RIT1-regulated pathways, and more.